Statin use is associated with lower risk of PTEN-null and lethal prostate cancer.

CONCLUSIONS: Molecular tumor classification identified PTEN and inflammation/immune activation as potential mechanisms linking statins with lower lethal prostate cancer risk. These findings support a potential causal association and could inform selection of relevant biomarkers for statin clinical trials.
PMID: 31754047 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - November 20, 2019 Category: Cancer & Oncology Authors: Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA Tags: Clin Cancer Res Source Type: research